Vivesto AB announced that positive preclinical data was obtained supporting continued development of the candidate drug Cantrixil within the indications bladder and blood cancer. The data indicates that Cantrixil has suitable drug properties and an acceptable safety profile, with minimal unwanted effects. Data from ADME studies (Absorption, Distribution, Metabolism, and Excretion) and secondary pharmacology studies confirm that Cantrixil has suitable physicochemical properties and an acceptable safety profile with minimal off-target effects, supporting continued development in bladder and blood cancer indications.

Additional in vitro and in vivo studies are planned during 2024 to ensure the properties, safety and efficacy of the drug before proceeding to clinical trials. The preclinical data package for Cantrixil is currently being extended as bladder and blood cancers are indications that require routes of drug administration not investigated previously. Both bladder and blood cancer have high unmet medical needs and significant commercial potential.

Vivesto has already obtained positive results with Cantrixil, which has shown strong cytotoxic effects at low doses in cell lines derived from patients with untreated and relapse/refractory hematological cancers including leukemia, non-Hodgkin lymphoma and multiple myeloma.